Intelligence / Healthtech / New Clinical Trials / Boehringer Ingelheim
Boehringer Ingelheim
9 Nov 2026: Trial registered · A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 9 Nov 2026
- Title
- A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation
- Conditions
- Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- United States, Australia, Japan, South Korea, Spain
- Country
- United States
- Reference
- NCT07926334
- Location
- United States, Australia, Japan
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Boehringer Ingelheim
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Boehringer Ingelheim in our registers.
More from United States
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.